Growing burden of HPV incidence in women aged more than 30 years and prevalence of sexually transmitted diseases are major factors driving growth of global human papillomavirus testing market.

1. Human Papillomavirus (HPV) Testing
Market by Current Trends, Issues &
Challenges, 2016 - 2024

2. About Us
Persistence Market Research (PMR) is a market intelligence company, providing global business
information reports and services. Our exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers. We have an experienced team of
Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and
techniques to gather, and analyze information. Our business offerings represent the latest and the most
reliable information indispensable for businesses to sustain a competitive edge.
Each PMR Syndicated Research report covers a different sector - such as pharmaceuticals, chemical,
energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports
provide in-depth analysis and deep segmentation to possible micro levels. With a wider scope and stratified
research methodology, our syndicated reports strive to serve clients and satisfy their overall research
requirement.
Copyright © 2015 Persistence Market Research
All Rights Reserved. This document contains highly confidential information and is the sole property of
PMR. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of
PMR.
Human Papillomavirus (HPV) Testing Market, 2016 - 2024 Page | 2
PersistenceMarketResearch

3. Report Media Releases
1 Human Papillomavirus (HPV) Testing Market by Current Trends,
Issues & Challenges, 2016 - 2024
Human papilloma virus (HPV) is a group of 150 related viruses, 75% of which are responsible for warts on arms,
chest, feet, hands and 25% of HPV types called high risk HPV cause cancer of genital. Human papillomavirus testing
is done for the screening of a several cancers including cervical cancer, vaginal cancer, vulvar cancer etc. Population
based studies by Center for Disease Control and Prevention (CDC) show that 66% of cervical cancers, 79% of anal
cancers, 55% of vaginal cancers and 62% of oropharangeal cancers in the U.S. are associated with HPV infection in
women. FDA approved human papillomavirus test as a preliminary screening test for cervical cancer. Even though the
test has been approved by FDA, it can only be used in conjunction with the Pap smear test – a gold standard test for
cervical cancer screening. Conventional human papillomavirus testing uses molecular biology techniques such as
nucleic acid probes labelled with radioactive isotopes. Insufficiency of these tests to detect all oncogenic and non-
oncogenic HPV types is the biggest restraint for the HPV testing market. Introduction of new techniques for HPV
screening such as DNA hybridization signal amplification system has opened up lucrative opportunities for the
manufacturers of human papillomavirus testing kits. New techniques for HPV testing use Southern blotting,
polymerase chain reaction (PCR) etc. for detection of HPV, species identification (genotyping) and detection of viral
load. HPV test is recommended for the women aged above 30 years and is not used in adolescents.
Request to view TOC : http://www.persistencemarketresearch.com/toc/11737
Growing burden of HPV incidence in women aged more than 30 years and prevalence of sexually transmitted
diseases are major factors driving growth of global human papillomavirus testing market. According to World Health
Organization (WHO) statistics, HPV related cervical cancer is the second most common cancer in women accounting
for 13% of cancer deaths in the U.S. Moreover, as per Morbidity and Mortality Weekly Report by CDC, currently 79
Mn people in U.S. are infected with HPV with the addition of 14 Mn new HPV infections each year. Lack of clear
guidelines for HPV testing and less adoption of new HPV testing methods by health practitioners are the factors
limiting the growth of global human papillomavirus testing market.
The global market for human papillomavirus testing market is segmented on basis of technology, disease indication,
end user and geography:
 Segmentation by Technology
o DNA Probe Technology
o RNA Probe Technology
 Segmentation by Disease Indication
o Cervical Cancer
o Vaginal Cancer
o Anal Cancer
o Others
 Segmentation by End User
o Hospitals
o Diagnostic Centers
Human Papillomavirus (HPV) Testing Market, 2016 - 2024 Page | 3
PersistenceMarketResearch

4. o Research Centers
Introduction of next generation HPV testing techniques for identification of type 16 and 18 HPV in samples is expected
to boost the growth of human papillomavirus testing market over the forecast period. Based on technology, human
papillomavirus tests are classified as DNA probe technology, and RNA probe technology. DNA probe technology
segment is foreseen to lead the market owing to more number of approved products for HPV testing using DNA
probes. The segment is expected to grow rapidly over the forecast period due to increasing adoption of the technique
for cervical cancer screening by healthcare professionals.
Based on disease indication, cervical cancer segment is expected to contribute largest share in global human
papillomavirus testing market due to availability of clear guidelines for the use of HPV test in cervical cancer
screening. Based on end users, the global human papillomavirus testing market has been segmented into hospitals,
clinics, Diagnostic Centers and Research Centers. Hospital end user segment is expected to contribute the maximum
share among end users.
On the basis of regional presence, global human papillomavirus testing market is segmented into five key regions viz.
North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is expected to lead the
global human papillomavirus testing market for due to high prevalence HPV related diseases. According to WHO
statistics, prevalence of HPV is high in developed countries such as U.S. and U.K.
Some of the major players in global human papillomavirus testing market are Digene Corporation, Roche Molecular
Systems, Inc, Hologic, Inc., Abbott Laboratories, Qiagen NV etc.
The report covers exhaustive analysis on:
 Human Papillomavirus Testing Market Segments
 Human Papillomavirus Testing Market Market Dynamics
 Historical Actual Market Size, 2013 - 2015
 Human Papillomavirus Testing Market Size & Forecast 2016 to 2024
 Human Papillomavirus Testing Market Current Trends/Issues/Challenges
 Competition & Companies involved
 Human Papillomavirus Testing Market Drivers and Restraints
Request to view Sample Report :
http://www.persistencemarketresearch.com/samples/11737
Report Highlights:
 Shifting Industry dynamics
 In-depth market segmentation
 Historical, current and projected industry size Recent industry trends
 Key Competition landscape
 Strategies of key players and product offerings
 Potential and niche segments/regions exhibiting promising growth
 A neutral perspective towards market performance
For information regarding permissions, contact:
Human Papillomavirus (HPV) Testing Market, 2016 - 2024 Page | 4
PersistenceMarketResearch

5. Persistence Market Research
90 Sate Street, Suite 700 Albany, NY 12207
Tel: +1-518-618-1030
Email: sales@persistencemarketresearch.com
media@persistencemarketresearch.com
Website: http://www.persistencemarketresearch.com/
Human Papillomavirus (HPV) Testing Market, 2016 - 2024 Page | 5
PersistenceMarketResearch